Latest Articles
Correlation Between Hormonal Modulation and Pregnancy Outcomes: The Impact of Estrogen Priming and Endometrial Receptivity in Intrauterine Insemination - Cureus
Correlation Between Hormonal Modulation and Pregnancy Outcomes: The Impact of Estrogen Priming and Endometrial Receptivity in Intrauterine Insemination Cureus
Published: June 4, 2025, 3:34 p.m.
Paula S. Cousins Ovarian & Endometrial Cancer Foundation, Inc. is this week’s winner of Loving Giving Local - yourerie.com
Paula S. Cousins Ovarian & Endometrial Cancer Foundation, Inc. is this week’s winner of Loving Giving Local yourerie.com
Published: June 4, 2025, 2:22 p.m.
Upregulation of miR-183 inhibits the invasion and migration of endometrial stromal cells in endometriosis patients by downregulating Ezrin - Frontiers
Upregulation of miR-183 inhibits the invasion and migration of endometrial stromal cells in endometriosis patients by downregulating Ezrin Frontiers
Published: June 3, 2025, 6:52 p.m.
Impact of the Microcystic, Elongated, and Fragmented (MELF) Invasion Pattern on prognosis in Endometrial Carcinoma: A Comprehensive Meta-Analysis - Frontiers
Impact of the Microcystic, Elongated, and Fragmented (MELF) Invasion Pattern on prognosis in Endometrial Carcinoma: A Comprehensive Meta-Analysis Frontiers
Published: June 3, 2025, 2:36 p.m.
Genmab advances with lower dose of Rina-S in endometrial cancer trials - Investing.com Canada
Genmab advances with lower dose of Rina-S in endometrial cancer trials Investing.com Canada
Published: June 3, 2025, 8:43 a.m.
Genmab advances with lower dose of Rina-S in endometrial cancer trials - Investing.com
Genmab advances with lower dose of Rina-S in endometrial cancer trials Investing.com
Published: June 3, 2025, 8:41 a.m.
Genmab A/S (GMAB) Reports 50% Response Rate With Rina-S in Advanced Endometrial Cancer - Insider Monkey
Genmab A/S (GMAB) Reports 50% Response Rate With Rina-S in Advanced Endometrial Cancer Insider Monkey
Published: June 3, 2025, 5 a.m.
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - BioSpace
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial BioSpace
Published: June 2, 2025, 11:48 p.m.
Genmab (GMAB) Announces Promising Rina-S Data from Endometrial C - GuruFocus
Genmab (GMAB) Announces Promising Rina-S Data from Endometrial C GuruFocus
Published: June 2, 2025, 7:20 p.m.
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial - GlobeNewswire
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial GlobeNewswire
Published: June 2, 2025, 6:32 p.m.
Link copied to clipboard!